Last reviewed · How we verify
Telbivudine treatment
Telbivudine is a nucleoside reverse transcriptase inhibitor that blocks hepatitis B virus reverse transcriptase, preventing viral replication.
Telbivudine is a nucleoside reverse transcriptase inhibitor that blocks hepatitis B virus reverse transcriptase, preventing viral replication. Used for Chronic hepatitis B infection.
At a glance
| Generic name | Telbivudine treatment |
|---|---|
| Sponsor | Southeast University, China |
| Drug class | Nucleoside reverse transcriptase inhibitor (NRTI) |
| Target | Hepatitis B virus reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | FDA-approved |
Mechanism of action
Telbivudine is a thymidine nucleoside analog that inhibits hepatitis B virus (HBV) reverse transcriptase, an enzyme essential for viral DNA synthesis. By incorporating into the growing HBV DNA chain, it causes chain termination and reduces viral load in patients with chronic hepatitis B infection.
Approved indications
- Chronic hepatitis B infection
Common side effects
- Myopathy
- Elevated creatine kinase
- Lactic acidosis
- Hepatitis flare
- Nausea
- Fatigue
Key clinical trials
- Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)
- Carvedilol for Prevention of Esophageal Varices Progression (NA)
- Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV (NA)
- Extension Study of Carvedilol RCT Study (NA)
- Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B (PHASE2)
- Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients
- FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
- Improvement of Hard Endpoint in Chronic Hepatitis B Patients Treated With Antiviral Therapy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Telbivudine treatment CI brief — competitive landscape report
- Telbivudine treatment updates RSS · CI watch RSS
- Southeast University, China portfolio CI